- Home
- LMB vs EWTX Comparison
LMB vs EWTX Comparison
Compare LMB & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- EWTX
- Stock Information
- Founded
- LMB 1901
- EWTX 2017
- Country
- LMB United States
- EWTX United States
- Employees
- LMB N/A
- EWTX N/A
- Industry
- LMB Engineering & Construction
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- EWTX Health Care
- Exchange
- LMB Nasdaq
- EWTX Nasdaq
- Market Cap
- LMB 1.7B
- EWTX 1.5B
- IPO Year
- LMB 2014
- EWTX 2021
- Fundamental
- Price
- LMB $133.84
- EWTX $14.12
- Analyst Decision
- LMB Strong Buy
- EWTX Buy
- Analyst Count
- LMB 3
- EWTX 9
- Target Price
- LMB $140.67
- EWTX $39.89
- AVG Volume (30 Days)
- LMB 224.2K
- EWTX 571.1K
- Earning Date
- LMB 08-05-2025
- EWTX 08-07-2025
- Dividend Yield
- LMB N/A
- EWTX N/A
- EPS Growth
- LMB 31.50
- EWTX N/A
- EPS
- LMB 2.78
- EWTX N/A
- Revenue
- LMB $532,913,000.00
- EWTX N/A
- Revenue This Year
- LMB $22.19
- EWTX N/A
- Revenue Next Year
- LMB $8.71
- EWTX N/A
- P/E Ratio
- LMB $48.13
- EWTX N/A
- Revenue Growth
- LMB 3.62
- EWTX N/A
- 52 Week Low
- LMB $48.17
- EWTX $10.60
- 52 Week High
- LMB $154.05
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- LMB 47.55
- EWTX 52.19
- Support Level
- LMB $115.10
- EWTX $13.34
- Resistance Level
- LMB $128.45
- EWTX $14.66
- Average True Range (ATR)
- LMB 7.02
- EWTX 0.59
- MACD
- LMB -2.50
- EWTX 0.15
- Stochastic Oscillator
- LMB 51.48
- EWTX 72.86
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.